ID   PERQ2_HUMAN             Reviewed;        1299 AA.
AC   Q6Y7W6; O75137; Q7Z2Z8; Q7Z3I2; Q96HU4; Q9NV82;
DT   09-JAN-2007, integrated into UniProtKB/Swiss-Prot.
DT   05-JUL-2004, sequence version 1.
DT   21-MAR-2012, entry version 69.
DE   RecName: Full=PERQ amino acid-rich with GYF domain-containing protein 2;
DE   AltName: Full=GRB10-interacting GYF protein 2;
DE   AltName: Full=Trinucleotide repeat-containing gene 15 protein;
GN   Name=GIGYF2; Synonyms=KIAA0642, PERQ2, TNRC15;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION.
RC   TISSUE=Kidney;
RX   MEDLINE=22803289; PubMed=12771153; DOI=10.1074/jbc.M211572200;
RA   Giovannone B., Lee E., Laviola L., Giorgino F., Cleveland K.A.,
RA   Smith R.J.;
RT   "Two novel proteins that are linked to insulin-like growth factor
RT   (IGF-I) receptors by the Grb10 adapter and modulate IGF-I signaling.";
RL   J. Biol. Chem. 278:31564-31573(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RX   MEDLINE=98403880; PubMed=9734811; DOI=10.1093/dnares/5.3.169;
RA   Ishikawa K., Nagase T., Suyama M., Miyajima N., Tanaka A., Kotani H.,
RA   Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. X.
RT   The complete sequences of 100 new cDNA clones from brain which can
RT   code for large proteins in vitro.";
RL   DNA Res. 5:169-176(1998).
RN   [3]
RP   SEQUENCE REVISION.
RX   MEDLINE=22158633; PubMed=12168954; DOI=10.1093/dnares/9.3.99;
RA   Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.;
RT   "Construction of expression-ready cDNA clones for KIAA genes: manual
RT   curation of 330 KIAA cDNA clones.";
RL   DNA Res. 9:99-106(2002).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-1096 (ISOFORM 1).
RC   TISSUE=Teratocarcinoma;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   GLN-1211 DEL.
RC   TISSUE=Fetal kidney, and Uterus;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1054-1299 (ISOFORM 1), AND
RP   VARIANT GLN-1211 DEL.
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-26, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=15302935; DOI=10.1073/pnas.0404720101;
RA   Beausoleil S.A., Jedrychowski M., Schwartz D., Elias J.E., Villen J.,
RA   Li J., Cohn M.A., Cantley L.C., Gygi S.P.;
RT   "Large-scale characterization of HeLa cell nuclear phosphoproteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:12130-12135(2004).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-26; SER-30; SER-158;
RP   SER-236; SER-242 AND THR-382, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-26, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RX   PubMed=17693683; DOI=10.1074/mcp.M700120-MCP200;
RA   Tang L.-Y., Deng N., Wang L.-S., Dai J., Wang Z.-L., Jiang X.-S.,
RA   Li S.-J., Li L., Sheng Q.-H., Wu D.-Q., Li L., Zeng R.;
RT   "Quantitative phosphoproteome profiling of Wnt3a-mediated signaling
RT   network: indicating the involvement of ribonucleoside-diphosphate
RT   reductase M2 subunit phosphorylation at residue serine 20 in canonical
RT   Wnt signal transduction.";
RL   Mol. Cell. Proteomics 6:1952-1967(2007).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-26; SER-30 AND SER-236,
RP   AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-26; SER-30; SER-160;
RP   SER-189; SER-236; THR-382 AND SER-593, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-19; SER-20; THR-25;
RP   SER-26; SER-30; SER-160; THR-373; SER-376 AND THR-382, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-26; SER-236; THR-370;
RP   THR-373 AND THR-382, AND MASS SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-26; SER-30 AND THR-382,
RP   AND MASS SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [16]
RP   VARIANTS PARK11 ALA-112; VAL-278; THR-335; THR-457; GLU-606 AND
RP   ILE-1242, AND VARIANTS SER-56; THR-460; ARG-1171; GLN-1211 DEL AND
RP   GLN-1212 INS.
RX   PubMed=18358451; DOI=10.1016/j.ajhg.2008.01.015;
RA   Lautier C., Goldwurm S., Duerr A., Giovannone B., Tsiaras W.G.,
RA   Pezzoli G., Brice A., Smith R.J.;
RT   "Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial
RT   Parkinson disease.";
RL   Am. J. Hum. Genet. 82:822-833(2008).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-26, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18187866; DOI=10.2116/analsci.24.161;
RA   Imami K., Sugiyama N., Kyono Y., Tomita M., Ishihama Y.;
RT   "Automated phosphoproteome analysis for cultured cancer cells by two-
RT   dimensional nanoLC-MS using a calcined titania/C18 biphasic column.";
RL   Anal. Sci. 24:161-166(2008).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-26 AND SER-30, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
CC   -!- FUNCTION: May act cooperatively with GRB10 to regulate tyrosine
CC       kinase receptor signaling, including IGF1 and insulin receptors.
CC   -!- SUBUNIT: Interacts with GRB10 (By similarity).
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q6Y7W6-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q6Y7W6-3; Sequence=VSP_022244;
CC         Note=No experimental confirmation available;
CC   -!- DISEASE: Defects in GIGYF2 are may be the cause of Parkinson
CC       disease type 11 (PARK11) [MIM:607688]. A complex neurodegenerative
CC       disorder characterized by bradykinesia, resting tremor, muscular
CC       rigidity and postural instability, as well as by a clinically
CC       significant response to treatment with levodopa. The pathology
CC       involves the loss of dopaminergic neurons in the substantia nigra
CC       and the presence of Lewy bodies (intraneuronal accumulations of
CC       aggregated proteins), in surviving neurons in various areas of the
CC       brain.
CC   -!- SIMILARITY: Belongs to the PERQ family.
CC   -!- SIMILARITY: Contains 1 GYF domain.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA31617.2; Type=Erroneous initiation;
CC       Sequence=BAA91873.1; Type=Miscellaneous discrepancy; Note=Unlikely isoform;
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY176045; AAO46889.1; -; mRNA.
DR   EMBL; AB014542; BAA31617.2; ALT_INIT; mRNA.
DR   EMBL; AK001739; BAA91873.1; ALT_SEQ; mRNA.
DR   EMBL; BX537885; CAD97881.1; -; mRNA.
DR   EMBL; BX538321; CAD98095.1; -; mRNA.
DR   EMBL; BC008072; AAH08072.2; -; mRNA.
DR   IPI; IPI00647635; -.
DR   IPI; IPI00784233; -.
DR   PIR; T00377; T00377.
DR   RefSeq; NP_001096616.1; NM_001103146.1.
DR   RefSeq; NP_056390.2; NM_015575.3.
DR   UniGene; Hs.565319; -.
DR   HSSP; Q9FT92; 1WH2.
DR   ProteinModelPortal; Q6Y7W6; -.
DR   SMR; Q6Y7W6; 530-591.
DR   IntAct; Q6Y7W6; 10.
DR   MINT; MINT-1365781; -.
DR   STRING; Q6Y7W6; -.
DR   DMDM; 74710467; -.
DR   PRIDE; Q6Y7W6; -.
DR   DNASU; 26058; -.
DR   Ensembl; ENST00000373563; ENSP00000362664; ENSG00000204120.
DR   Ensembl; ENST00000409547; ENSP00000386537; ENSG00000204120.
DR   Ensembl; ENST00000414511; ENSP00000416486; ENSG00000204120.
DR   GeneID; 26058; -.
DR   KEGG; hsa:26058; -.
DR   UCSC; uc002vtg.2; human.
DR   UCSC; uc002vth.2; human.
DR   CTD; 26058; -.
DR   GeneCards; GC02P233562; -.
DR   H-InvDB; HIX0002929; -.
DR   HGNC; HGNC:11960; GIGYF2.
DR   MIM; 607688; phenotype.
DR   MIM; 612003; gene.
DR   neXtProt; NX_Q6Y7W6; -.
DR   Orphanet; 2828; Young adult-onset Parkinsonism.
DR   eggNOG; NOG330740; -.
DR   GeneTree; ENSGT00650000093073; -.
DR   HOVERGEN; HBG082121; -.
DR   OMA; PPHMGEL; -.
DR   OrthoDB; EOG40VVP7; -.
DR   NextBio; 47940; -.
DR   ArrayExpress; Q6Y7W6; -.
DR   Bgee; Q6Y7W6; -.
DR   CleanEx; HS_GIGYF2; -.
DR   Genevestigator; Q6Y7W6; -.
DR   GO; GO:0008219; P:cell death; IEA:UniProtKB-KW.
DR   InterPro; IPR003169; GYF.
DR   Pfam; PF02213; GYF; 1.
DR   SMART; SM00444; GYF; 1.
DR   SUPFAM; SSF55277; GYF; 1.
DR   PROSITE; PS50829; GYF; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Complete proteome; Disease mutation;
KW   Neurodegeneration; Parkinson disease; Parkinsonism; Phosphoprotein;
KW   Polymorphism; Reference proteome.
FT   CHAIN         1   1299       PERQ amino acid-rich with GYF domain-
FT                                containing protein 2.
FT                                /FTId=PRO_0000270837.
FT   DOMAIN      533    581       GYF.
FT   REGION      547    563       Required for GRB10-binding (By
FT                                similarity).
FT   COMPBIAS    106    111       Poly-Gly.
FT   COMPBIAS    118    272       Arg-rich.
FT   COMPBIAS    436    473       Pro-rich.
FT   COMPBIAS    607   1025       Gln-rich.
FT   COMPBIAS    738    888       Glu-rich.
FT   COMPBIAS   1198   1252       Gln-rich.
FT   MOD_RES      19     19       Phosphoserine.
FT   MOD_RES      20     20       Phosphoserine.
FT   MOD_RES      25     25       Phosphothreonine.
FT   MOD_RES      26     26       Phosphoserine.
FT   MOD_RES      30     30       Phosphoserine.
FT   MOD_RES     158    158       Phosphoserine.
FT   MOD_RES     160    160       Phosphoserine.
FT   MOD_RES     189    189       Phosphoserine.
FT   MOD_RES     236    236       Phosphoserine.
FT   MOD_RES     242    242       Phosphoserine.
FT   MOD_RES     370    370       Phosphothreonine.
FT   MOD_RES     373    373       Phosphothreonine.
FT   MOD_RES     376    376       Phosphoserine.
FT   MOD_RES     382    382       Phosphothreonine.
FT   MOD_RES     593    593       Phosphoserine.
FT   VAR_SEQ     177    177       V -> VGKKNGYYCMYSPVLLLGQPLCQ (in isoform
FT                                2).
FT                                /FTId=VSP_022244.
FT   VARIANT      56     56       N -> S (may be associated with PARK11).
FT                                /FTId=VAR_044439.
FT   VARIANT     112    112       T -> A (in PARK11).
FT                                /FTId=VAR_044440.
FT   VARIANT     278    278       I -> V (in PARK11).
FT                                /FTId=VAR_044441.
FT   VARIANT     335    335       S -> T (in PARK11).
FT                                /FTId=VAR_044442.
FT   VARIANT     423    423       P -> L (in dbSNP:rs34845648).
FT                                /FTId=VAR_051268.
FT   VARIANT     457    457       N -> T (in PARK11).
FT                                /FTId=VAR_044443.
FT   VARIANT     460    460       P -> T (in dbSNP:rs2289912).
FT                                /FTId=VAR_044444.
FT   VARIANT     606    606       D -> E (in PARK11).
FT                                /FTId=VAR_044445.
FT   VARIANT    1171   1171       H -> R.
FT                                /FTId=VAR_044446.
FT   VARIANT    1211   1211       Missing.
FT                                /FTId=VAR_044447.
FT   VARIANT    1212   1212       Q -> QQ.
FT                                /FTId=VAR_044448.
FT   VARIANT    1242   1242       V -> I (in PARK11).
FT                                /FTId=VAR_044449.
FT   CONFLICT    365    365       Missing (in Ref. 2; BAA31617).
FT   CONFLICT    792    792       E -> G (in Ref. 5; CAD98095).
FT   CONFLICT   1153   1153       D -> G (in Ref. 5; CAD98095).
SQ   SEQUENCE   1299 AA;  150070 MW;  2282458102F64B71 CRC64;
     MAAETQTLNF GPEWLRALSS GGSITSPPLS PALPKYKLAD YRYGREEMLA LFLKDNKIPS
     DLLDKEFLPI LQEEPLPPLA LVPFTEEEQR NFSMSVNSAA VLRLTGRGGG GTVVGAPRGR
     SSSRGRGRGR GECGFYQRSF DEVEGVFGRG GGREMHRSQS WEERGDRRFE KPGRKDVGRP
     NFEEGGPTSV GRKHEFIRSE SENWRIFREE QNGEDEDGGW RLAGSRRDGE RWRPHSPDGP
     RSAGWREHME RRRRFEFDFR DRDDERGYRR VRSGSGSIDD DRDSLPEWCL EDAEEEMGTF
     DSSGAFLSLK KVQKEPIPEE QEMDFRPVDE GEECSDSEGS HNEEAKEPDK TNKKEGEKTD
     RVGVEASEET PQTSSSSARP GTPSDHQSQE ASQFERKDEP KTEQTEKAEE ETRMENSLPA
     KVPSRGDEMV ADVQQPLSQI PSDTASPLLI LPPPVPNPSP TLRPVETPVV GAPGMGSVST
     EPDDEEGLKH LEQQAEKMVA YLQDSALDDE RLASKLQEHR AKGVSIPLMH EAMQKWYYKD
     PQGEIQGPFN NQEMAEWFQA GYFTMSLLVK RACDESFQPL GDIMKMWGRV PFSPGPAPPP
     HMGELDQERL TRQQELTALY QMQHLQYQQF LIQQQYAQVL AQQQKAALSS QQQQQLALLL
     QQFQTLKMRI SDQNIIPSVT RSVSVPDTGS IWELQPTASQ PTVWEGGSVW DLPLDTTTPG
     PALEQLQQLE KAKAAKLEQE RREAEMRAKR EEEERKRQEE LRRQQEEILR RQQEEERKRR
     EEEELARRKQ EEALRRQREQ EIALRRQREE EERQQQEEAL RRLEERRREE EERRKQEELL
     RKQEEEAAKW AREEEEAQRR LEENRLRMEE EAARLRHEEE ERKRKELEVQ RQKELMRQRQ
     QQQEALRRLQ QQQQQQQLAQ MKLPSSSTWG QQSNTTACQS QATLSLAEIQ KLEEERERQL
     REEQRRQQRE LMKALQQQQQ QQQQKLSGWG NVSKPSGTTK SLLEIQQEEA RQMQKQQQQQ
     QQHQQPNRAR NNTHSNLHTS IGNSVWGSIN TGPPNQWASD LVSSIWSNAD TKNSNMGFWD
     DAVKEVGPRN STNKNKNNAS LSKSVGVSNR QNKKVEEEEK LLKLFQGVNK AQDGFTQWCE
     QMLHALNTAN NLDVPTFVSF LKEVESPYEV HDYIRAYLGD TSEAKEFAKQ FLERRAKQKA
     NQQRQQQQLP QQQQQQPPQQ PPQQPQQQDS VWGMNHSTLH SVFQTNQSNN QQSNFEAVQS
     GKKKKKQKMV RADPSLLGFS VNASSERLNM GEIETLDDY
//
